Wide Ranks

AUPH

Aurinia Pharmaceuticals Inc

8.85

Top Statistics
Market Cap 1 B Forward PE 15.39 Revenue Growth 24.30 %
Current Ratio 5.60 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -10.23 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 2033.84 Enterprise / Revenue 4.57 Price To Sales Trailing12 Months 5.75
Profitability
Profit Margins -10.23 % Operating Margins 17.33 %
Balance Sheet
Total Cash 348 M Total Cash Per Share 2.43 Total Debt 87 M
Total Debt To Equity 22.64 Current Ratio 5.60 Book Value Per Share 2.71
All Measures
Short Ratio 552.00 % Message Board Id finmb_882669 Fax 250 708 4345
Shares Short Prior Month 7 M Return On Equity -0.0578 City Edmonton
Uuid 6af70c53-6225-3411-b004-ce20a00fb8bf Previous Close 8.71 First Trade Date Epoch Utc 1 B
Book Value 2.71 Beta 1.46 Total Debt 87 M
Volume 1 M Price To Book 3.26 Fifty Two Week Low 4.71
Total Cash Per Share 2.43 Total Revenue 220 M Shares Short Previous Month Date 1 B
Target Median Price 11.00 Audit Risk 4 Max Age 86400
Recommendation Mean 1.71 Sand P52 Week Change 0.3133 Operating Margins 17.33 %
Target Mean Price 10.84 Net Income To Common -22552000 Short Percent Of Float 0.0483
Implied Shares Outstanding 143 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 348 M
Next Fiscal Year End 1 B Revenue Per Share 1.54 Held Percent Insiders 0.0719
Ebitda Margins 0.22 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 2 Regular Market Previous Close 8.71
Target Low Price 8.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.53
Open 8.75 Free Cashflow 38 M State AB
Dividend Yield 0.00 % Return On Assets -0.0215 Time Zone Short Name EST
Board Risk 10 Trailing Eps -0.1500 Day Low 8.70
Address1 118 Avenue , 14315 Shares Outstanding 143 M Compensation Risk 6
Price Hint 2 Target High Price 13.00 Website https://www.auriniapharma.com
52 Week Change 0.0243 Average Volume 1 M Forward Eps 0.5400
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 489.40 %
Is_sp_500 False Regular Market Day High 8.91 Profit Margins -10.23 %
Debt To Equity 22.64 Fifty Two Week High 9.74 Day High 8.91
Shares Short 6 M Regular Market Open 8.75 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 4.57 Revenue Growth 24.30 %
Shares Percent Shares Out 0.0480 Operating Cashflow 28 M Currency USD
Time Zone Full Name America/New_York Market Cap 1 B Is_nasdaq_100 False
Zip T5L 4S6 Quote Type EQUITY Industry Biotechnology
Long Name Aurinia Pharmaceuticals Inc. Overall Risk 6 Regular Market Day Low 8.70
Held Percent Institutions 0.4273 Current Price 8.85 Address2 Suite 140
Enterprise To Ebitda 2033.84 Financial Currency USD Current Ratio 5.60
Gross Margins 76.86 % Industry Disp Biotechnology Number Of Analyst Opinions 7
Country Canada Float Shares 128 M Two Hundred Day Average 6.10
Governance Epoch Date 1 B Ir Website http://www.isotechnika.com/for_investors/ Price To Sales Trailing12 Months 5.75
Enterprise Value 1 B Forward PE 15.39 Regular Market Volume 1 M
Ebitda 495000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.

It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

It has a collaboration and license agreement with Otsuka Pharmaceutical Co.

, Ltd.

The company was incorporated in 1993 and is headquartered in Edmonton, Canada.